Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Loredana Urso, Ilaria Cavallari, Micol Silic-Benussi, Lorena Biasini, Giulia Zago, Fiorella Calabrese, Pier Franco Conte, Vincenzo Ciminale, Giulia Pasello

Research output: Contribution to journalArticlepeer-review


Malignant Pleural Mesothelioma (MPM) is a chemoresistant tumor characterized by low rate of p53 mutation and upregulation of Murine Double Minute 2 (MDM2), suggesting that it may be effectively targeted using MDM2 inhibitors. In the present study, we investigated the anticancer activity of the MDM2 inhibitors Nutlin 3a (in vitro) and RG7112 (in vivo), as single agents or in combination with rhTRAIL. In vitro studies were performed using MPM cell lines derived from epithelioid (ZL55, M14K), biphasic (MSTO211H) and sarcomatoid (ZL34) MPMs. In vivo studies were conducted on a sarcomatoid MPM mouse model. In all the cell lines tested (with the exception of ZL55, which carries a biallelic loss-of-function mutation of p53), Nutlin 3a enhanced p21, MDM2 and DR5 expression, and decreased survivin expression. These changes were associated to cell cycle arrest but not to a significant induction of apoptosis. A synergistic pro-apoptotic effect was obtained through the association of rhTRAIL in all the cell lines harboring functional p53. This synergistic interaction of MDM2 inhibitor and TRAIL agonist was confirmed using a mouse preclinical model. Our results suggest that the combined targeting of MDM2 and TRAIL might provide a novel therapeutic option for treatment of MPM patients, particularly in the case of sarcomatoid MPM with MDM2 overexpression and functional inactivation of wild-type p53.

Original languageEnglish
Pages (from-to)44232-44241
Number of pages10
Issue number27
Publication statusPublished - Jan 1 2017


  • MDM2
  • Mesothelioma
  • P53
  • RG7112

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists'. Together they form a unique fingerprint.

Cite this